annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 42H Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with
advanced non-small cell lung cancer (NSCLC): Preliminary results of a
randomized phase III Hellenic Oncology Research Group trial. (Abstract
#7605)
A. Karampeazis, L. Vamvakas, A. G. Pallis, C. Christophyllakis, N. K. Kentepozidis,
V. Chandrinos, A. Polyzos, A. Athanasiadis, G. Milaki, V. Georgoulias
Brd. 43A Prognostic versus predictive value of EML4-ALK translocation in metastatic
non-small cell lung cancer. (Abstract #7606)
A. T. Shaw, B. Yeap, D. B. Costa, B. J. Solomon, E. L. Kwak, A. T. Nguyen,
K. Bergethon, J. A. Engelman, A. J. Iafrate
Brd. 43B Use of germline polymorphisms in VEGF to predict tumor response and
progression-free survival in non-small cell lung cancer (NSCLC) patients
treated with sorafenib: Subset pharmacogenetic analysis of Eastern
Cooperative Oncology Group (ECOG) trial E2501. (Abstract #7607)
W. Zhang, J. Lee, J. H. Schiller, D. P. Carbone, C. H. Chung, H. Lenz
Brd. 43D Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-
Integrated Approaches of Targeted Therapy for Lung Cancer Elimination
(BATTLE) trial. (Abstract #7609)
R. S. Herbst, G. R. Blumenschein Jr., E. S. Kim, J. Lee, A. S. Tsao, C. M. Alden,
S. Liu, D. J. Stewart, I. I. Wistuba, W. K. Hong
Brd. 43E EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of
the outcome of cisplatin plus pemetrexed treated patients. (Abstract #7610)
G. Altavilla, M. Santarpia, C. Arrigo, M. Rizzo, G. Galletti, G. Marabello, A. Gnani,
V. Pitini
Brd. 43F Molecular profiling of smoking-related non-small cell lung cancer (NSCLC)
phenotypes. (Abstract #7611)
J. H. Strickler, W. Mostertz, M. Stevenson, J. Crawford, N. Ready, W. Barry,
A. Potti
Brd. 43G In vivo assessment of the effects of bevacizumab in advanced non-small cell
lung cancer (NSCLC). (Abstract #7612)
R. S. Heist, G. D. Duda, D. Sahani, N. A. Pennell, J. W. Neal, M. Ancukiewicz,
J. A. Engelman, T. J. Lynch, R. K. Jain
Brd. 43H Eicosanoids in non-small cell lung cancer (NSCLC). (Abstract #7613)
D. H. Johnson, L. Horn, Z. Zhao, G. Milne, J. Morrow, A. Sandler, Y. Shyr,
D. P. Carbone
Brd. 44A Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung
cancer: Cancer and Leukemia Group B 150304. (Abstract #7614)
M. J. Edelman, L. Hodgson, X. F. Wang, R. Christenson, E. E. Vokes,
R. A. Kratzke
Brd. 44B Correlation of pharmacogenetic markers with docetaxel-based
chemotherapy resistance in patients with advanced/metastatic non-small cell
lung cancer. (Abstract #7615)
C. Papadaki, E. Tsaroucha, L. Kaklamanis, D. Mavroudis, E. Lagoudaki,
M. Trypaki, E. Tsakalaki, V. Georgoulias, I. Sougklakos
Brd. 44C Correlation of genetic polymorphisms in folate metabolic pathway genes
with clinical outcomes in pemetrexed-treated advanced NSCLC patients.
(Abstract #7616)
J. Kim, J. Yun, J. Kong, S. Lee, S. Kim, J. Lee, J. Ahn, K. Park, M. Ahn
Brd. 44D Phase II trial of personalized chemotherapy in stage IV NSCLC: Clinical
application of functional profiling in first-line therapy. (Abstract #7617)
R. A. Nagourney, J. B. Blitzer, E. A. Deo, R. Nandan, R. Shuman, T. Asciuto,
D. McConnell, M. Paulsen, S. S. Evans
Brd. 44E Clinical outcomes (CO) for special populations of patients (pts) with
advanced non-small cell lung cancer (NSCLC): Results from ARIES, a
bevacizumab (BV) observational cohort study (OCS). (Abstract #7618)
A. J. Wozniak, J. Garst, M. Jahanzeb, M. P. Kosty, R. Vidaver, S. Beatty, S. Teng,
E. D. Flick, A. Sing, T. J. Lynch, for the ARIES Investigators
220